Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
European Society of Cardiology Congress 2008
Maintained Lipid Lowering and LDL Targets: Study Results Confirmed
Munich, Germany / August 30-September 3, 2008
Munich - Aggressive LDL-C reduction was not found effective for reducing a composite end point of major cardiovascular (CV) events in patients with aortic stenosis, despite a 61.3% LDL reduction. Lipid lowering did reduce ischemic events in...
European Society of Cardiology Congress 2008
Another Piece of the Puzzle: Clarifying the Role of Statins in Chronic Heart Failure
Munich, Germany / August 30-September 3, 2008
Munich - The ability of statins to prevent cardiovascular (CV) events by lowering LDL levels is one of the most convincing therapeutic advances of modern medicine. Whether as secondary prevention for recurrent CV events, such as myocardial...
European Society of Cardiology Congress 2008
SEAS: Results on Safety and Efficacy
Munich, Germany / August 30-September 3, 2008
Munich - Aggressive LDL-C reduction was not found effective for reducing a composite end point of major cardiovascular (CV) events in patients with aortic stenosis, despite a 61.3% LDL reduction. Lipid lowering did reduce ischemic events in...
European Society of Cardiology Congress 2008
Meeting the Unmet Needs of Patients with Acute Coronary Syndrome
Munich, Germany / August 30-September 3, 2008
Munich - Antiplatelet therapy is the cornerstone of acute and longer-term management of patients with acute coronary syndrome (ACS). However, among other factors, the speed of onset and offset of action of antiplatelet agents has been...
European Society of Cardiology Congress
TRANSCEND: Angiotensin Receptor Inhibition in High-risk Cardiovascular Patients Intolerant to ACE Inhibitors
Munich, Germany / August 30-September 3, 2008
Munich - A new study has provided evidence-based guidance for reducing the risk of cardiovascular events in the estimated 25% of patients who are intolerant to ACE inhibitors. In patients on optimal therapies, including antihypertensive...
European Society of Cardiology Congress 2008
The Role of Novel Anticoagulants in Acute Coronary Syndrome and Atrial Fibrillation
Munich, Germany / August 30-September 3, 2008
Munich - A novel oral anticoagulant is part of a wave of new agents designed to avoid the limitations of warfarin and the heparins. The recent progress is being made possible by success in identifying new targets along the coagulation...
European Society of Cardiology Congress 2008
Targeting Platelet Aggregation in the Continuum of ACS Care: Progress Being Made Towards Improved Outcomes
Munich, Germany / August 30-September 3, 2008
INTRODUCTION Antiplatelet therapy has proven to be invaluable in the management of acute coronary syndrome (ACS), reducing ischemic events to a considerable degree in every patient group. Early introduction is also associated with the...
European Society of Cardiology Congress 2008
More Rapid, More Complete and More Consistent Platelet Inhibition: New Options for the Management of ACS Patients
Munich, Germany / August 30-September 3, 2008
Munich - Platelet aggregation is a pivotal event in acute coronary syndromes (ACS) and platelet inhibition is mandatory to prevent further thrombotic events. Until now, ASA and the irreversible thienopyridine, clopidogrel, have successfully...
PRIORITY PRESS - 31st Annual Congress of the European Society of Cardiology
Enhanced Antiplatelet Strategies for Patients with Acute Coronary Syndrome
Barcelona, Spain / August 29-September 2, 2009
Barcelona - Newly completed clinical trials with antiplatelet therapies may alter how thrombotic events are prevented in acute coronary syndromes. In two trials, a reduction in thrombotic events was achieved without increasing risk of major...